Phase 2 Trial of ALK-001 in Stargardt Disease and Treatment Indications for Dry AMD/GA
Time: 11:15 am
day: Day Two
- ALK-001 is a first in class inhibitor of vitamin A dimerization
- Results of a randomized, placebo-controlled, clinical trial indicates that
- ALK-001 has disease modifying ability on the progression of Stargardt Disease
- ALK-001 is also being tested in Geographic Atrophy associated with dry-AMD in a fully enrolled Phase 3 study.